Clinical trials: Intestinal Transit
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Cystic Fibrosis
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Many people with Cystic Fibrosis (CF) are troubled by symptoms from their stomach and bowels: their gastrointestinal (GI) tract.
- Trial name
- GIFT-CF1 (NCT03566550)
- Testing
- MRI scans
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Constipation
B. Lactis HN019 for Functional Constipation
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.
- Trial name
- CTT (NCT01463293)
- Testing
- B. lactis HN019
- Where
- 12 sites in United States
- Volunteers
- 224 people
- Sponsor
- Fonterra Research Centre
Constipation
Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Patients with constipation often have bloating and abdominal distension. It is unclear if this is related to intestinal bacteria.
- Trial name
- NCT00844831
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Louisville
Constipation-predominant Irritable Bowel Syndrome
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor.
- Trial name
- NCT01085643
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Idiopathic Constipation
Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
The purpose of this study is to determine if lubiprostone may change the rate of movement of food and activities in the stomach and intestines in subjects whose gastrointestinal (GI) tract is slower due to constipation.
- Trial name
- NCT01469819
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Constipation-predominant Irritable Bowel Syndrome
Cheno Effect on Transit in Health and IBS-C
The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
- Trial name
- Chenotransit (NCT00912301)
- Testing
- Sodium chenodeoxycholate (NaCDC)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome, Constipation
Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or discomfort in association with altered bowel habit.
- Trial name
- NCT01162863
- Testing
- Lubiprostone, Smartpill wireless motility capsule
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan
Pill Capsule Endoscopy Completion Rates
Study of Metoclopramide in Small Bowel Capsule Endoscopy
Patients undergoing small bowel capsule endoscopy will be randomized into 3 study groups to either receive 5 mg of metoclopramide, 10 mg of metoclopramide, or a placebo 30 minutes prior to swallowing the Pill Cam.
- Trial name
- NCT01630109
- Testing
- Metoclopramide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ascension Health
Cystic Fibrosis Gastrointestinal Disease
Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
The investigators will recruit 15 patients with cystic fibrosis 18 years of age and older who present with constipation. The investigators will assess baseline motility symptoms with a survey.
- Trial name
- NCT04210427
- Testing
- Polyethylene Glycol 3350, SmartPill Motility System & PillCam Patency Capsule
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- St. Louis University
Food Selection
Pilot Study Using a Wireless Motility Capsule
Research suggests dietary fiber may decrease transit time through the gastrointestinal tract. Research studies traditionally use radio-opaque markers to determine gastric emptying, colonic transit, and whole gut transit time.
- Trial name
- NCT01102894
- Testing
- SmartPill
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test.
- Conditions
- Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
- Trial name
- NCT00577772
- Testing
- Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome, Diarrhea
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
Our hypothesis is that the medication approved for treatment of high blood cholesterol levels, Colesevelam HCl (WELCHOL), decreases colonic transit and permeability in patients with diarrhea due to irritable bowel syndrome.
- Trial name
- welchol (NCT00911612)
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Effects of 2 Mu-opiates on Gastrointestinal Transit
Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
Tapentadol is FDA approved for the treatment of moderate to severe acute pain. Due to the dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there is potential for off label use in chronic pain.
- Trial name
- tap-oxy (NCT01500317)
- Testing
- Tapentadol, Oxycodone
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic